A composite indicator of derived neutrophil–lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors

A composite indicator of derived neutrophil–lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors

BackgroundThere are currently no established biomarkers that can predict whether advanced pancreatic carcinoma (PC) patients would benefit from immune checkpoint inhibitors (ICIs). Our study investigated whether the pretreatment composite biomarker of derived neutrophil–lymphocyte ratio (dNLR) and l...

Full description

Bibliographic Details
Main Authors: Shiyun Chen, Shiyuan Guo, Miaomiao Gou, Yuting Pan, Mengjiao Fan, Nan Zhang, Zhaoli Tan, Guanghai Dai
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
pancreatic cancer
immune checkpoint inhibitors
overall survival
progression-free survival
derived neutrophil–lymphocyte ratio
lactate dehydrogenase
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.951985/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.951985/full

Similar Items